PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?

Shares of Precigen PGEN have soared nearly 43% in the past week after the company provided an encouraging regulatory update for its lead pipeline program.

Last week, Precigen announced that it has completed a rolling submission for a biologic license application (BLA) seeking the FDA’s accelerated approval for PRGN-2012, an experimental gene therapy to treat adults with recurrent respiratory papillomatosis (RRP).

A rare disease, RRP causes benign tumors (called papillomas) to grow in the respiratory tract, most commonly in the larynx (voice box). It is caused by two types of human papilloma virus (HPV) – HPV 6 and HPV 11.

More on PGEN’s BLA Filing for PRGN-2012

The BLA is supported by data from a pivotal phase I/II study that evaluated PRGN-2012 for the treatment of adult patients with RRP. Data from the study showed that more than 50% of patients achieved a complete response (defined as the percentage of patients who require no RRP surgeries). Also, more than 85% of patients experienced a reduction in surgical interventions in the year after receiving PRGN-2012 compared to the year before receiving the therapy.

The regulatory filing is currently in the initial 60-day review period and the FDA will decide whether to accept the application for further review and set the target action by this period. Management has requested a priority review for this filing, which, if granted, will reduce the agency’s review period by four months.

If the FDA approves this filing, PRGN-2012 will be the first FDA-approved therapeutic for adults with RRP. The disease currently has no cure, and the standard treatment involves repeated surgeries. However, these procedures only manage symptoms and do not address the root cause of the disease, often leading to a cycle of recurrences. It has been observed that patients with RRP frequently require surgeries over their lifetime.

Management expects a potential approval for PRGN-2012 before this year’s end. The gene therapy has already received breakthrough therapy and orphan drug designation from the FDA in RRP indication.

PGEN Stock Performance

In the past year, Precigen’s shares have lost 13.9% compared with the industry’s 13.6% fall.

Zacks Investment Research
Image Source: Zacks Investment Research

Other Players in the RRP Space

Another company developing its own RRP medication is Inovio INO, which is evaluating INO-3107 in a pivotal phase I/II study. However, the Inovio drug is an investigational DNA medicine designed to generate an antigen-specific T-cell response against both HPV-6 and HPV-11 proteins.

Management plans to submit a regulatory filing with the FDA in mid-2025 seeking accelerated approval for the drug in the RRP indication.

Like PRGN-2012, the FDA has also granted breakthrough therapy and orphan drug designations to INO-3107 in RRP indication.

PGEN’s Zacks Rank

Precigen currently carries a Zacks Rank #3 (Hold).

Precigen, Inc. Price

Precigen, Inc. Price

Precigen, Inc. price | Precigen, Inc. Quote

Key Picks Among Biotech Stocks

Some better-ranked stocks from the sector are Castle Biosciences CSTL and CytomX Therapeutics CTMX, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Bottom-line estimates for Castle Biosciences have improved from a loss of 59 cents per share to earnings of 34 cents for 2024 in the past 60 days. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.15 to $1.84. In the past year, shares of Castle Biosciences have surged 28.2%.

CSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.

In the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 29 cents to 5 cents. Estimates for 2025 loss per share have narrowed from 56 cents to 35 cents during the same timeframe. CTMX’s shares have lost 36.8% in the past year.

CytomX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%.

Just Released: Zacks Top 10 Stocks for 2024

Hurry – you can still get in early on our 10 top tickers for 2025. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2025. You can still be among the first to see these just-released stocks with enormous potential.
 

See New Top 10 Stocks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 5 Stocks Set to Double. Click to get this free report

Inovio Pharmaceuticals, Inc. (INO) : Free Stock Analysis Report

CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report

Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report

Precigen, Inc. (PGEN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.